Company Profile

Public information reviewed
Adagene Inc. logo

Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer.

USNASDAQ: ADAG
Public sources
1 reviewed
Published leadership records
17
Last reviewed
Sep 12, 2026
View sources

Agent View

Machine representations

Inspect the same governed public record as Markdown, structured data, or a retrieval endpoint.

Markdown

https://registry.alpha.ac/companies/adagene-inc.md
Open Markdown

Adagene Inc.

Alpha governed public record. Unknown, unavailable, and unpublished values are never inferred as zero.

Record

FieldValue
Representationalpha-profile-markdown-v3
ProtocolAlpha Governance Facts Protocol 0.1
Schemaalpha.governance.entity.public.v1
Record versionpublic-1
Canonical entityalpha:company:b925afbb-e483-491c-b195-7a680f06601e
Entity typeCompany
Canonical URLhttps://registry.alpha.ac/companies/adagene-inc
PublicationPUBLISHED
Verificationsource_reported
Verification schemaalpha-verification-states-v1
Ownershipunclaimed
Published claims22
Claims under review1
Evidence records2
Conflicts0
Conflicts in internal review0
Observed2026-09-12T21:32:05.800844+00:00
Last reviewed2026-09-12T21:32:05.800844+00:00

Identity

  • Legal name: Adagene Inc.
  • Display name: Adagene Inc.

Leadership

  • Peter Luo, Ph.D: Co-Founder, Chief Executive Officer, President of R&D, and Chairman of the Board. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Andy (Yiu Leung) Cheung: Independent Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Cuong Do: Independent Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Li Zhu, Ph.D.: Independent Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Man Kin (Raymond) Tam, M.B.A., B. Eng.: Chief Financial Officer and Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Ulf Grawunder, Ph.D.: Independent Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Alexander Goergen: Vice President, Head of Business Development. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Guizhong Liu, Ph.D.: Senior Vice President of Early Drug Discovery. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Jiping Zha: Executive Vice President of Clinical Development. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Man Kin (Raymond) Tam, M.B.A., B. Eng.: Chief Financial Officer and Director. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Mickael Chane-Du: Chief Strategy Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Peter Luo, Ph.D: Co-Founder, Chief Executive Officer, President of R&D, and Chairman of the Board. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Qinghai Zhao, Ph.D: Chief Manufacturing Officer. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Songmao Zheng, Ph.D.: Senior Vice President of Clinical Pharmacology and Quantitative Sciences. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Wenlin Zeng: Vice President of Early Stage CMC. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Xiaohong (Kristine) She: Senior Vice President, Head of Clinical Operations. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.
  • Yan Li, M.B.A.: Senior Vice President, Bioinformatics and Information Technology. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:2.

Roles

  • PUBLISHED

Governance

  • NOT_ASSERTED

Board committees

  • PUBLISHED

Financials

  • NOT_ASSERTED

Workforce

  • NOT_ASSERTED

Market and index context

  • PUBLISHED

Legal Name

  • Adagene Inc.. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:1.

Headquarters

  • US. Publication: UNDER_REVIEW. Verification: source_reported. Assertion: source_reported. Evidence: unlinked, under review.

Entity Status

  • Public listing published. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:1.

Published Fact

  • US. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:1.
  • Healthcare. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:1.
  • Biotechnology. Publication: PUBLISHED. Verification: source_reported. Assertion: source_reported. Evidence: alpha:evidence:company:b925afbb-e483-491c-b195-7a680f06601e:1.

Coverage states

FieldValue
IdentityPUBLISHED
BusinessPUBLISHED
LeadershipPUBLISHED
Board and committeesPUBLISHED
GovernanceNOT_ASSERTED
FinancialsNOT_ASSERTED
WorkforceNOT_ASSERTED
OwnershipNOT_ASSERTED
RatingsNOT_PUBLISHED
Market and index contextPUBLISHED

Public sources

Rights

FieldValue
public_retrievalallowed
agent_retrievalallowed
redistributionnot_granted
model_trainingnot_granted
commercial_usenot_specified
relationship_pathfindingnot_granted
direct_contactnot_granted

Limitations

  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.

Alternate representations